Type 2 diabetes mellitus
Conditions
Interventions
Canagliflozin 100mg/day for 3months
Sitagliptin 50mg/day for 3months
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)before test registration - the meal and exercise cure for one month or more or a meal and an exercise cure, and diabetic medicine and inpatient 2)HbA1c(NGSP):more than 7.0%, less than 14.0% 3)eGFR more than 45ml/min/1.73m 2 4)Type 2 diabetes 5)Pts with written IC 6)Age more than 20, less than 65 7)Diabetic macular edema
Exclusion criteria
Exclusion criteria: 1)Patients treated with photocoagulation, anti-VEGF drugs or steroids to intraocular within 6 months 2)severe ketosis, diabetic coma within 6 months 3)severe infection, before operation, severe trauma 4)severe hepatic dysfunction 5)Patients who use of insulin, GLP-1 receptor agonist or diuretic 6)pregnacy 7)Allergy for sitagliptin, nateglinide,liraglutide and exenatide 8)Patients judged by the investigator to be ineligible for some other reason .
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change from baseline in retinal central foveal thickness using optical coherence tomography (OCT) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Mean change at 3 months and 2 years after administration of canagliflozin or sitagliptin Glucose HbA1c Body weight Lipid Blood pressure Endo-PAT 2) Number of times that were treated with anti-VEGF drugs in 2 years | — |
Countries
Japan
Contacts
Public ContactJoe Nagakura
Yokohama City University Medical Center Department of Endocrinology and Diabetes
Outcome results
None listed